Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors' reply

TY - JOUR

T1 - Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors' reply

AU - KEYNOTE-057 investigators

AU - Balar, Arjun V.

AU - Kamat, Ashish M.

AU - de Wit, Ronald

N1 - Funding Information: AVB reports research funding from AstraZeneca/MedImmune, Genentech/Roche, Merck Sharp & Dohme, and Seattle Genetics; has been a consultant to AstraZeneca/MedImmune, Cerulean Pharma, Genentech/Roche, Incyte, Merck Sharp & Dohme, Pfizer/EMD Serono, and Seattle Genetics/Astellas; and honoraria from AstraZeneca/MedImmune, Genentech/Roche, and Merck Sharp & Dohme. AMK reports research funding from FKD Industries and Merck Sharp & Dohme; honoraria from UroToday Publishing and EAU (EU Oncology); has been a consultant to Merck Sharp & Dohme, Bristol Myers Squibb, Imagin, Eisai, Arquer, MDX Health, Photocure, AstraZeneca, Tesaro, Abbott Molecular, US Biotest, Ferring, and BioClinica; travel expenses from Pfizer Japan; holds patents for CyPRIT-Cytokine Panel for Response to Intravesical Immunotherapy; and is the president of the International Bladder Cancer Group and the International Bladder Cancer Network. RdW reports research funding from Bayer and Sanofi; has been a consultant to Astellas, Merck Sharp & Dohme, Roche/Genentech, and Sanofi; and honoraria from Astellas, Bayer, Janssen, Merck Sharp & Dohme, Roche/Genentech, and Sanofi.

PY - 2021/9/1

Y1 - 2021/9/1

UR - https://www.scopus.com/pages/publications/85114022737

U2 - 10.1016/S1470-2045(21)00478-2

DO - 10.1016/S1470-2045(21)00478-2

M3 - Article

C2 - 34478664

AN - SCOPUS:85114022737

SN - 1470-2045

VL - 22

SP - e380

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 9

ER -